- The FDA accepts under Priority Review Verastem's (NASDAQ:VSTM) marketing application seeking approval for duvelisib for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for relapsed/refractory follicular lymphoma (FL).
- The agency's action date is October 5.
- Shares are up 33% premarket on light volume.
- Previously: Verastem submits U.S. marketing application for lead candidate duvelisib; shares ahead 7% premarket (Feb. 7)
FDA accepts Verastem's marketing application for blood cancer med duvelisib, action date October 5; shares up 33% premarket
Recommended For You
About VSTM Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
VSTM | - | - |
Verastem, Inc. |